



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/618,481	07/11/2003	Tony Hollingsworth	NE-0004	8213

7590 03/17/2006
Jane Massey Licata
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053

EXAMINER

JOYCE, CATHERINE

ART UNIT PAPER NUMBER

1642

DATE MAILED: 03/17/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Art Unit: 1642

1. Claims 1-3 are pending, and claim 2 is withdrawn from consideration as being drawn to a non-elected invention
2. Claims 1 and 3 are under examination.
3. Applicant's election with traverse of Group I, claims 1 and 3, in the reply filed on January 12, 2006 is acknowledged. The traversal is on the ground(s) that searching Groups I and II together would not pose a search burden. This argument is not found persuasive because, while the searches for the inventions of groups I and II would be overlapping they would not be coextensive. The search for the invention of group I would include a search for a composition comprising the recited polypeptide, whatever the intended use of the composition, whereas a search for the method of method of group II would include a search on all methods of treating cancer with MUC-1 compositions, including DNA compositions. Therefore, a search for one group would not be coextensive with a search for the other group. Thus, the requirement for restriction is deemed proper and is therefore made FINAL.
4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1642

5. Claims 1 and 3 are rejected under 35 U.S.C. 102(b) as being anticipated by Hoover (1993, J. Clin. Oncol. 11(3):390-9), as evidenced by Byrd (2004, Cancer and Metastasis Review 23:77-99).

The claims are drawn to a composition for preventing or treating cancer in a subject comprising at least a portion of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1 (claim 1), wherein at least a portion of a MUC1 cytoplasmic peptide of SEQ ID NO:1 comprises a vaccine.

It is noted that the recitation of “for preventing or treating cancer” in claim 1 and “comprises a vaccine” are merely suggestive of an intended use and are not given weight for purposes of comparing the claims with the prior art. The claims read on the active ingredient *per se*, which is “at least a portion of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1”.

Hoover et al. describe clinical trials wherein patients with Dukes’ B2 or C3 were treated with an autologous tumor-bacillus Calmette-Guerin (BCG) vaccine composition (abstract). The vaccine compositions comprised a patient’s autologous tumors cells combined with bacillus Calmette-Guerin. As evidenced by Byrd et al., MUC-1 is expressed in colon cancer cells (page 82). Thus, the autologous tumor cell vaccine compositions of Hoover would comprise a cytoplasmic tail peptide of SEQ ID NO:1. Thus, all of the claim limitations are met.

6. Claims 1 and 3 are rejected under 35 U.S.C. 102(e) as being anticipated by WO 02/058450.

The claims are drawn to a composition for preventing or treating cancer in a subject comprising at least a portion of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1 (claim 1), wherein at least a portion of a MUC1 cytoplasmic peptide of SEQ ID NO:1 comprises a vaccine.

Art Unit: 1642

It is noted that the recitation of “for preventing or treating cancer” in claim 1 and “comprises a vaccine” are merely suggestive of an intended use and are not given weight for purposes of comparing the claims with the prior art. The claims read on the active ingredient *per se*, which is “at least a portion of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1”.

WO 02/058450 describes a composition comprising a polypeptide having the amino acid sequence of SEQ ID NO:1 of the instant application, which is a molecule comprising at least a portion of cytoplasmic tail, a composition comprising a polypeptide having the amino acid sequence of amino acid residues 1 to 42 of SEQ ID NO:1 of the instant application, which is a molecule comprising at least a portion of the cytoplasmic tail, and a composition comprising a polypeptide having the amino acid sequence of amino acid residues 22 to 72 of SEQ ID NO:1 of the instant application, which is a molecule comprising at least a portion of the cytoplasmic tail (page 46, Example 6, and Figure 7A). A comparison of the cited sequences with SEQ ID NO:1 is included herewith as an Appendix A to this Action.

7. Claims 1 and 3 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent 6,548,643.

The claims are drawn to a composition for preventing or treating cancer in a subject comprising at least a portion of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1 (claim 1), wherein at least a portion of a MUC1 cytoplasmic peptide of SEQ ID NO:1 comprises a vaccine.

It is noted that the recitation of “for preventing or treating cancer” in claim 1 and “comprises a vaccine” are merely suggestive of an intended use and are not given weight for purposes of comparing the claims with the prior art. The claims read on the active ingredient *per se*, which is “at least a portion of a MUC1 cytoplasmic tail peptide of SEQ ID NO:1”.

Art Unit: 1642

US Patent 6,548,643 teaches conjugates between an antigen and a carbohydrate polymer, wherein the conjugates may be immunogenic vaccines, and wherein the conjugates may especially comprise contain one or more repeated subunits of human mucin or non-repeated repeated regions of human mucin (abstract). US Patent 6,548,643 also teaches that immunogenic peptides may be derived from the extracellular region or intracellular region of MUC1 (column 8, lines 14-16), and that preferred peptides comprises amino acids 1-21 or 35-54 of the intracellular portion of MUC 1 (i.e. of SEQ ID NO:1 of the instant application) (columns 7 and 8, lines 25-43 and SEQ ID NOs:16 and 17), which are at least a portion of cytoplasmic tail. A comparison of the cited sequences with SEQ ID NO:1 is included herewith as an Appendix to this Action. Thus, all of the claim limitations are met.

8. No claims are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine M. Joyce whose telephone number is 571-272-3321. The examiner can normally be reached on Monday thru Friday, 10:15 - 6:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Susan Ungar
Susan Ungar
Primary Patent Examiner

Application/Control Number: 10/618,481

Page 6

Art Unit: 1642

Catherine Joyce
Examiner
Art Unit 1642

Appendix A, page 7

in the presence of the test compound.

Example 6; Fig 7A; 82pp; English.

The present sequence is the cytoplasmic domain (CD) of mucin MUC1, a glycoprotein expressed aberrantly at high levels over the surface of breast, prostate, lung and other types of carcinoma cells. MUC1 binds via its CD to c-Src, epidermal growth factor receptor (EGF-R), p120ctn and protein kinase C (PKC)-delta, c-Src, EGF-R and PKC-delta phosphorylate the MUC1 CD, leading to enhanced binding of beta-catenin to MUC1. The phosphorylation by EGF-R leads to enhanced binding of c-Src to MUC1. The invention features methods of identifying compounds that inhibit (a) the binding of MUC1 to a tumour progressor (e.g. beta-catenin, c-Src, EGF-R, p120ctn, or PKC-delta) and/or (b) phosphorylation of MUC1 by tumour progressors with kinase activity (e.g. c-Src, EGF-R or PKC-delta). The invention also includes a method for identifying a compound that enhances binding to, and phosphorylation of, MUC1 by glycogen synthase kinase 3-beta. An antisense oligonucleotide that hybridises to a MUC1 transcript or to a tumour progressor transcript can be used to inhibit expression of MUC1 or a tumour progressor in a cancer cell, especially a breast cancer cell, or a lung, colon, pancreatic, renal, stomach, liver, bone, haematological (e.g. leukaemia, lymphoma), neural tissue, melanoma, ovarian, testicular, prostate, cervical, vaginal, or bladder cancer cell. A peptide fragment (see ABB79644) of the MUC1 CD, or a polynucleotide encoding it, can be used to inhibit binding of MUC1 to beta-catenin in a cancer cell that expresses MUC1

Sequence 72 AA;

Query Match 100.0%; Score 395; DB 5; Length 72;

Best Local Similarity 100.0%; Pred. No. 8.2e-43; Mismatches 0; Indels 0; Gaps 0;

Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQCRKKNYGQDIPARDTHPMSEYPTHTGRTVPPSSIDRSFYKVSAGNGSSLSY 60

DB 1 CQCRKKNYGQDIPARDTHPMSEYPTHTGRTVPPSSIDRSFYKVSAGNGSSLSY 60

QY 61 TNPVAAAASNTL 72

DB 61 TNPVAAAASNTL 72

RESULT 2

ID ADY53531 standard; protein; 146 AA.

AC ADY53531;

DT 19-MAY-2005 (first entry)

DE Truncated MUC1 growth factor receptor isoform, SEQ ID 37.

KW antibody; antigen-binding fragment; MUC1 receptor;

KM growth factor receptor; cancer; cytostatic.

OS Homo sapiens.

PN WO2005019269-A2.

PD 03-MAR-2005.

PE 26-AUG-2004; 2004WO-US027954.

PR 26-AUG-2003; 2003US-0498260P.

PA (MINE-) MINERVA BIOTECHNOLOGIES CORP.

PI Banded CC;

DR WPI; 2005-214228/22.

PT N-PSDB; ADY53536.

PT tetrapeptide sequence which is portion of MUC1 receptor that functions as growth factor receptor, useful for diagnosing and treating cancer.

Claim 68; SEQ ID NO 37; 204pp; English.

The invention relates to a novel antibody or its antigen-binding fragment that specifically binds to a tetrapeptide sequence which is a portion of a MUC1 receptor that functions as a growth factor receptor. The invention further comprises a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. The antibody or its antigen-binding fragment is useful for treating a subject having cancer caused by aberrant expression of MUC1, which involves administering the antibody or its antigen-binding fragment in an amount effective to block interaction of a natural ligand and portion of the receptor that remains attached to the cell surface after cleavage of the receptor, or in an amount effective to reduce shedding of an interchain binding region of the MUC1 receptor. The antibody or its antigen-binding fragment has cytostatic activity. The cancer may be of the breast, prostate, lung, ovary, colorectal, pancreas and brain. The antibody or its antigen-binding fragment is useful for determining aggressiveness and/or metastatic potential of a cancer, which involves contacting a sample obtained from a subject suspected of having cancer with the antibody or its antigen-binding fragment that specifically binds to peptides expressed on the cell surface, and determining the amount of the antibody or its antigen-binding fragment bound to the sample. The antibody or its antigen-binding fragment is useful for diagnosing the presence of absence of cancer or the aggressiveness of a cancer. This sequence represents a truncated MUC1 growth factor receptor isoform of the invention.

Sequence 146 AA;

Query Match 100.0%; Score 395; DB 9; Length 146;

Best Local Similarity 100.0%; Pred. No. 2.1e-42; Mismatches 0; Indels 0; Gaps 0;

Matches 72; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CQCRKKNYGQDIPARDTHPMSEYPTHTGRTVPPSSIDRSFYKVSAGNGSSLSY 60

DB 75 CQCRKKNYGQDIPARDTHPMSEYPTHTGRTVPPSSIDRSFYKVSAGNGSSLSY 134

QY 61 TNPVAAAASNTL 72

DB 135 TNPVAAAASNTL 146

RESULT 3

ID ADY53532 standard; protein; 171 AA.

AC ADY53532;

DT 19-MAY-2005 (first entry)

DE Truncated MUC1 growth factor receptor isoform, SEQ ID 38.

KW antibody; antigen-binding fragment; MUC1 receptor;

KM growth factor receptor; cancer; cytostatic.

OS Homo sapiens.

PN WO2005019269-A2.

PD 03-MAR-2005.

PE 26-AUG-2004; 2004WO-US027954.

PR 26-AUG-2003; 2003US-0498260P.

PA (MINE-) MINERVA BIOTECHNOLOGIES CORP.

PI Banded CC;

DR WPI; 2005-214228/22.

RESULT 3
US-09-134-916A-2
Sequence 2, Application US/09134916A
Patent No. 6328956
GENERAL INFORMATION:
APPLICANT: CHAMON, Pierre
APPLICANT: KIENY, Marie-Paule
APPLICANT: LATHIE, Richard
APPLICANT: HAREUVENI, Mara
TITLE OF INVENTION: PHARMACEUTICAL COMPOSITION FOR THE
TREATMENT OR PREVENTION OF A MALIGNANT TUMOR
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/134,916A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/479,537
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: FR 90/13101
FILING DATE: 23-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/FR91/00835
FILING DATE: 23-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/039,320
FILING DATE: 04-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/403,576
FILING DATE: 14-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 017753-025
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-6620
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 2035 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
FEATURE:
NAME/KEY: Peptide
LOCATION: 128..1899
OTHER INFORMATION: /note= "The amino acids spanning
128 to 1899 constitute a repeated region wherein the repeat
OTHER INFORMATION: 20 amino acids, 17 of which are fixed. The number of such
OTHER INFORMATION: repeats varies from 1 to 40."
FEATURE:
NAME/KEY: Peptide
LOCATION: 134
OTHER INFORMATION: /note= "Amino acid 134 is X1 = Xaa
OTHER INFORMATION: Xaa Xaa which is the codon for Pro or Ala wherein Pro = CCT,
OTHER INFORMATION: CCC, CCA, or CCG; and Ala = GCT, GCC, GCA, or GCG."
FEATURE:
NAME/KEY: Peptide

LOCATION: 144
OTHER INFORMATION: /note= "Amino acid 144 is Y = Xaa
OTHER INFORMATION: which is the codon for Thr or Asn wherein Thr = ACT, ACC, ACU
OTHER INFORMATION: or ACG; and Asn = AAT or AAC."
FEATURE:
NAME/KEY: Peptide
LOCATION: 147
OTHER INFORMATION: /note= "Amino acid 147 is X2 = Xaa
OTHER INFORMATION: which is the codon for Pro or Ala wherein Pro = CCT, CCC, CCU
OTHER INFORMATION: or CCG; and Ala = GCT, GCC, GCA, or GCG."
FEATURE:
NAME/KEY: Peptide
LOCATION: 1..21
OTHER INFORMATION: /note= "Amino acids 1 to 21 are a
OTHER INFORMATION: 21 amino acid precursor sequence."
US-09-134-916A-2
Query Match 99.0%; Score 391; DB 2; Length 2035;
Best Local Similarity 98.6%; Pred. No. 2.2e-39;
Matches 71; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CQCRKNYGQDIFPARDYHPSSEYPTHTHGRYPSSSTDRSPYKVSAGNGSSISY 60
DB 1964 CQCRKNYGQDIFPARDYHPSSEYPTHTHGRYPSSSTDRSPYKVSAGNGSSISY 2023
QY 61 TNPAAVAASNL 72
DB 2024 TNPAAVAASNL 2035
RESULT 4
US-09-593-870A-16
Sequence 16, Application US/09593870A
Patent No. 6548643
GENERAL INFORMATION:
APPLICANT: McKenzie, Ian F.C.
APPLICANT: Apostolopoulos, Vasso
APPLICANT: Pletersz, Geoff Allan
TITLE OF INVENTION: Antigen Carbohydrate Compounds and Their
FILE REFERENCE: Use in Immunotherapy
CURRENT APPLICATION NUMBER: US/09/593,870A
PRIOR FILING DATE: 2000-06-14
PRIOR APPLICATION NUMBER: 09/223,043
NUMBER OF SEQ ID NOS: 69
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 16
LENGTH: 23
TYPE: PRT
ORGANISM: Homo sapiens
US-09-593-870A-16
Query Match 31.4%; Score 124; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e-08;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CQCRKNYGQDIFPARDYH 21
DB 3 CQCRKNYGQDIFPARDYH 23
RESULT 5
US-09-593-870A-17
Sequence 17, Application US/09593870A
Patent No. 6548643
GENERAL INFORMATION:
APPLICANT: McKenzie, Ian F.C.
APPLICANT: Apostolopoulos, Vasso
APPLICANT: Pletersz, Geoff Allan
TITLE OF INVENTION: Antigen Carbohydrate Compounds and Their
FILE REFERENCE: Use in Immunotherapy
FILE REFERENCE: 2368-McKenzie

Appendix B, page 1

```

: CURRENT APPLICATION NUMBER: US/09/593,870A
:
: CURRENT FILING DATE: 2000-06-14
:
: PRIOR APPLICATION NUMBER: 09/223,043
:
: PRIOR FILING DATE: 1998-12-30
:
: NUMBER OF SEQ ID NOS: 69
:
: SOFTWARE: FastSeq for Windows Version 3.0
:
: SEQ ID NO 17
:
: LENGTH: 20
:
: TYPE: PRT
:
: ORGANISM: Homo sapiens
:
: US-09-593-870A-17

```

Query Match	27.1%;	Score 107;	DB 2;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 1.3e-06;		
Matches	20;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0;

Qy	35	YVPPSSTRDRSPYEKVSAGNG	54
Db	1	YVPPSSTRDRSPYEKVSAGNG	20

```

RESULT 6
US-09-593-870A-48
Sequence 48: Application US/09593870A
Patent No. 6548643
GENERAL INFORMATION:
APPLICANT: McKenzize, Ian F.C.
APPLICANT: Apostolopoulos, Vaseo
APPLICANT: Pietersz Geoff Allan
TITLE OF INVENTION: Antigen Carbohydrate C
TITLE OF INVENTION: Use in Immunotherapy
FILE REFERENCE: 2368-McKenzie
CURRENT APPLICATION NUMBER: US/09/593,870A
CURRENT FILING DATE: 2000-06-14
PRIOR APPLICATION NUMBER: 09/4223,043
PRIOR FILING DATE: 1998-12-30
NUMBER OF SEQ ID NOS: 69
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 48
LENGTH: 21
TYPE: PRF
ORGANISM: Homo sapiens
US-09-593-870A-48

```

Query Match	27.1%	Score 107	DB 2	Length 21
Best Local Similarity	100.0%	Pred. No. 1.3e-06		
Matches	20	Conservative	0	Mismatches 0; Indels 0; Gaps 0
QY	35	YYPBSTDRSPYKVSAGNG	54	
Db	2	YYPBSTDRSPYKVSAGNG	21	

RESULT 7
US-08-560-005-3
; Sequence 3, Application US/08560005

```

1  GENERAL INFORMATION:
2
3  APPLICANT:  Pot, David A.
4
5  APPLICANT:  Williams, Lewis T.
6
7  APPLICANT:  Jefferson, Anne Bennett
8
9  APPLICANT:  Majerus, Philip W.
10
11 TITLE OF INVENTION:  No. 6001354el Grb2 Associating Protein and Nucleic
12
13 TITLE OF INVENTION:  Acids Encoding Therefor
14
15 NUMBER OF SEQUENCES:  10
16
17 CORRESPONDENCE ADDRESS:
18
19 ADDRESSEE:  Townsend and Townsend and Crew
20
21 STREET:  One Market Plaza, Steuart Tower, Suite 2000
22
23 CITY:  San Francisco
24
25 STATE:  California
26
27 COUNTRY:  USA
28
29 ZIP:  94105
30
31 COMPUTER READABLE FORM:

```

```

?      MEDIUM TYPE: Floppy disk
?      COMPUTER: IBM PC compatible
?      OPERATING SYSTEM: PC-DOS/MS-DOS
?      SOFTWARE: Patent In Release #1.0, Versi
?      CURRENT APPLICATION DATA:
?      FILING DATE:
?      CLASSIFICATION: 435
?      ATTORNEY/AGENT INFORMATION:
?      NAME: Dow, Karen B.
?      REGISTRATION NUMBER: 29,684
?      REFERENCE /DOCKET NUMBER: 2307K-0624000
?      TELECOMMUNICATION INFORMATION:
?      TELEPHONE: 415-326-2400
?      TELEFAX: 415-326-2422
?      INFORMATION FOR SEQ ID NO: 3 :
?      SOURCE CHARACTERISTICS:
?      LENGTH: 398 amino acids
?      TYPE: amino acid
?      TOPOLOGY: linear
?      MOLECULE TYPE: protein
?      FEATURE:
?      NAME/KEY: Region
?      LOCATION: 1..398
?      OTHER INFORMATION: /note= "celegprase"
?
US-08-560-005-3

```

Query Match	18.1%;	Score 71.5;	DB 2;	Length 398;
Best Local Similarity	31.5%;	Pred. No. 1.4;		
Matches	28;	Conservative	11;	Mismatches 23;
				Indels 27;
				Gaps 5.

```

QY      6 KNYGGOLDIPADT-----YH--PMSEYPTVH-----HGKVPSPSTDR 43
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      190 KNGTHEILDTRGQKALVERDAFIGHEQPTVFEPYRVTVGTTEODGKRV-PSWTR 248
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY      44 SPEKVSAGNGSSLSYTNPAVMAASAL 72
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db      249 ILYK-----GDGITGLSYTNKKAAVADSL 273
          ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

RESULT 8
US-09-418-540-3
; Sequence 3, Application US/09418540
; Patent No. 6296848

1 APPLICANT: Pot, David A.
2 APPLICANT: Williams, Lewis T.
3 APPLICANT: Jefferson, Anne Bennett
4 APPLICANT: Majerub, Philip W.
5 TITLE OF INVENTION: No. 6296848e1 Grb2 Associating Protein and Nucleic
6 TITLE OF INVENTION: Acids Encoding Therefor
7 NUMBER OF SEQUENCES: 10
8
9 CORRESPONDENCE ADDRESS:
10 ADDRESSEE: Townsend and Crew
11 STREET: One Market Plaza, Stewart Tower, Suite 2000
12 CITY: San Francisco
13 STATE: California
14 COUNTRY: USA

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/418,540
FILING DATE: 14-OCT-1999
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/560,005
FILING DATE: 17-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Dow, Karen B.